CRISPR QC key facts
as of Oct 2026- Developer of an analytics platform designed to simulate the gene editing process before introduction to cells.
- CRISPR QC is valued at approximately $25.0M as of Oct 2026 (last reported valuation).
- It has raised $11.6M.
- Notable investors include MedTech Innovator, Keiretsu Forum, CONNECT (San Diego), Serra Ventures, BioTools Innovator — 9 tracked in total.
- Status: Privately Held (backing).
CRISPR QC's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch CRISPR QC: the Monday email on marks, rounds and moves
CRISPR QC funding rounds
No funding rounds for CRISPR QC are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
CRISPR QC valuation
CRISPR QC's last reported valuation was $25 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
CRISPR QC investors
9 investors are on record for CRISPR QC, including MedTech Innovator, Keiretsu Forum, CONNECT (San Diego) and Serra Ventures.
About CRISPR QC
Developer of an analytics platform designed to simulate the gene editing process before introduction to cells. The company's platform provides key cornerstones of information and insight fundamental to realizing the full potential and quality control for clustered regularly interspaced short palindromic repeats gene editing, enabling scientists to increase editing efficiency and define a strategy to achieve better outcomes at the cellular level.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2021
- Employees
- 12
- Website
- crisprqc.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.